As a senior scientist at Adimab, my work focuses on identifying and engineering protein therapeutics that target peptide-HLA (pHLA) complexes. This work has primarily focused on soluble T cell receptor (TCR)-based therapeutics and includes the development of a novel yeast-based platform to both discover and engineer soluble TCRs. Prior to joining Adimab, I completed my doctoral research at MIT in Prof. Michael Birnbaum’s lab, where I worked to characterize the peptide-binding repertoires of Class II HLA proteins.